{"filings":[{"id":746922,"accession_number":"0001171843-26-003793","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2026-05-29T20:15:18+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Edesa Biotech shareholders approve equity plan amendment adding 750K shares","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders approved Plan Amendment increasing shares available for issuance by 750,000 and eliminating annual per participant option grant limit.","All seven director nominees elected with over 2.6M votes for each; broker non-votes of ~2.15M on each.","Advisory vote on executive compensation approved with 2.67M for, 69K against.","Appointment of MNP LLP as auditors for FY2026 approved with 4.81M for.","Approximately 55% of outstanding shares (4.9M shares) represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":453556,"accession_number":"0001171843-26-003459","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2026-05-15T13:08:56+00:00","items":["5.02"],"status":"ready","headline":"Edesa Biotech CEO to receive 90% of salary as RSUs, up from 50%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Pardeep Nijhawan will receive 90% of monthly base salary as fully vested RSUs, effective May 13, 2026.","Previously, 50% of base salary was issued as RSUs; remaining 10% paid in cash for withholding and tax requirements.","RSUs granted each month at month-end fair market value under the 2019 Equity Incentive Compensation Plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":443876,"accession_number":"0001171843-26-003429","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2026-05-14T20:40:19+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edesa Biotech Q2 net loss widens to $4.2M; progresses EB06 vitiligo Phase 2 prep","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $4.2M ($0.49/sh) for Q2 FY2026 vs $1.6M ($0.30/sh) in prior year.","Operating expenses rose $2.7M to $4.3M on $2.3M R&D increase for EB06 and paridiprubart prep.","Cash and cash equivalents $10.0M; working capital $8.2M as of March 31, 2026.","EB06 Phase 2 vitiligo study on track; site activations and recruitment expected mid-2026 subject to approval.","Paridiprubart Phase 3 ARDS data showed consistent treatment benefits across disease subgroups and comorbidities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105252,"accession_number":"0001171843-26-001046","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Edesa Biotech reports Phase 3 paridiprubart cut 28-day mortality by 27% (p<0.001); 278-patient study positive","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Paridiprubart reduced adjusted 28-day mortality to 24% from 33% (27% relative risk reduction; p<0.001) in full 278-patient population.","Consistent benefit across severity groups: 35% reduction in non-IMV (n=174) and across comorbidities (sepsis, AKI, pneumonia).","Safety profile favorable; adverse events low and similar to placebo; over 400 patients now exposed.","Company filed provisional patent applications for paridiprubart in sepsis, acute kidney injury, and pneumonia."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105251,"accession_number":"0001171843-26-000810","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2026-02-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edesa Biotech Q1 FY2026 net loss $2.2M; progresses EB06 vitiligo Phase 2 prep","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $2.2M ($0.28/share) vs. $1.6M ($0.48/share) a year ago; operating expenses $2.3M.","Cash and equivalents $12.1M; working capital $12.0M at Dec 31, 2025.","EB06 (anti-CXCL10) manufacturing underway for Phase 2 vitiligo study; patient enrollment targeted mid-2026.","Paridiprubart Phase 3 ARDS data under subgroup analysis; plans to present at scientific conferences.","Participating in GVFS, BIO Europe Spring, ATS 2026 and other conferences March-May 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121504,"accession_number":"0001171843-25-007918","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Edesa Biotech increases ATM offering capacity to $2.26M; discloses prior sales of $3.72M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Prospectus supplement filed to increase max aggregate offering under ATM to $2,262,508.","Prior sales: $3.72M under Sept 2025 prospectus and $837K under Oct 2024 supplement.","Legal opinion of Fasken Martineau DuMoulin LLP regarding validity of shares attached."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121503,"accession_number":"0001171843-25-007913","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edesa reports FY2025 net loss $7.2M; Phase 3 paridiprubart meets endpoints","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $7.2M ($1.27/share) vs $6.2M ($1.93/share) prior year; OpEx $7.9M.","Cash $10.8M at Sept 30, 2025; raised $3.4M net from ATM post-year-end.","Phase 3 paridiprubart met primary/secondary endpoints; exploring partnerships.","Initiated manufacturing for Phase 2 EB06 vitiligo study; recruitment mid-2026.","Canadian gov't funding extended for respiratory program; JP Morgan meetings planned Jan 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121502,"accession_number":"0001171843-25-006690","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2025-10-28T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Edesa Biotech reports positive Phase 3 results for paridiprubart in ARDS; 28-day mortality reduced 13% absolute","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Paridiprubart + SOC reduced 28-day mortality to 39% vs 52% placebo (n=104; p<0.001): 13% absolute improvement, 25% relative risk reduction.","Durable survival benefit at 60 days: 46% vs 59% mortality (p=0.003); 13% absolute improvement, 22% relative risk reduction.","Paridiprubart arm showed 41% higher relative rate of clinical improvement (≥2-point WCSS improvement at Day 28; p=0.032).","Safety data from >275 subjects: paridiprubart generally well-tolerated, consistent with prior profile.","Paridiprubart also in U.S. government 'Just Breathe' study; program funded by Government of Canada's Strategic Innovation Fund."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138186,"accession_number":"0001171843-25-006188","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2025-09-30T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"Edesa Biotech amends CAD$23M gov't agreement, extends timeline to Dec 2028, shifts EB05 focus to general ARDS","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Project completion extended to December 31, 2028 (from December 31, 2025); agreement expiration extended to later of Dec 2045 or last repayment.","First annual repayment due in 2032 (from 2029) and only if the Company earns gross revenue.","Clinical focus for EB05 changed to general ARDS from COVID-19 induced ARDS; company gains access to fully funded US government platform study.","Amendment adds reporting requirements on similar EB05 development projects and updates milestones/timelines.","Government of Canada committed up to CAD$23M ($17M USD) in partially repayable funding under original agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138185,"accession_number":"0001171843-25-005800","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2025-09-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Edesa Biotech files prospectus supplement for up to $4.0M ATM offering through H.C. Wainwright","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ATM offering for up to $4,006,544 of common shares through H.C. Wainwright.","Previously sold $837,134 under existing ATM agreement from October 2024.","New shelf registration statement (S-3, File No. 333-288966) declared effective September 9, 2025.","Legal opinion from Fasken Martineau DuMoulin LLP on share validity included as exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138184,"accession_number":"0001171843-25-005235","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2025-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edesa Biotech reports Q3 net loss of $1.7M; advances EB06 manufacturing for vitiligo Phase 2","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $1.7M ($0.25/sh) for quarter ended June 30, 2025, unchanged from $1.7M ($0.52/sh) YoY.","Operating expenses flat at $1.9M; R&D $0.9M, G&A $1.0M.","Cash and cash equivalents $12.4M, working capital $12.1M at June 30, 2025.","EB06 Phase 2 vitiligo IND data submission to FDA planned by end of calendar 2025; manufacturing activities ongoing.","EB05 program benefits from fully funded U.S. government platform study; first randomizations completed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155616,"accession_number":"0001171843-25-003495","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Edesa Biotech shareholders approve 1.725M share increase to 2019 equity plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment to 2019 Equity Incentive Compensation Plan increasing share reserve by 1,725,000 shares.","Fungible share pool provisions removed; incentive stock option limit raised from 171,429 to 300,000 shares.","All seven director nominees elected: Chypyha, Liu, MacDonald, Marshall, Nijhawan, Olson, Sistilli.","Advisory vote on executive compensation approved with 2,215,325 for, 178,016 against.","MNP LLP appointed as independent auditor for fiscal year ending September 30, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155615,"accession_number":"0001171843-25-003183","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edesa Biotech reports Q2 net loss of $1.6M; advances vitiligo drug EB06 to Phase 2","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $1.6M ($0.30/share) vs $1.9M ($0.58) in prior-year Q2; operating expenses fell to $1.6M.","Completed $15M equity financing from institutional investors; cash and equivalents total $13.9M.","EB06 Phase 2 IND submission to FDA expected H2 2025; topline results 12-18 months after clearance.","EB05 ARDS study fully funded by government; R&D spend shifted from EB05 to EB06 program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155614,"accession_number":"0001171843-25-002027","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2025-04-04T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Edesa Biotech appoints Peter Weiler as CFO effective May 1, 2025, replacing Stephen Lemieux","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Stephen Lemieux resigns as CFO effective May 1, 2025, to pursue other opportunities; will continue as a senior financial advisor under a consulting agreement.","Peter J. Weiler appointed CFO effective May 1, 2025; base salary of $300,000 USD per annum, target annual bonus of 40% of base salary, and $2,000/month auto allowance.","Weiler previously served as President of Exzell Pharma, Inc., and held business development roles at Biosyent Inc. and Cipher Pharmaceuticals Inc.","If terminated without cause, Weiler receives 12-24 months base salary plus benefits; enhanced change-of-control severance of 24 months base salary.","Lemieux's departure not due to any disagreement with Edesa; transition is planned and orderly."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174112,"accession_number":"0001171843-25-000864","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2025-02-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edesa Biotech reports Q1 FY2025 net loss of $1.6M; raises $15M in private placement","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $1.6M ($0.48/share) compared to $1.7M ($0.54/share) in prior year quarter.","R&D expenses rose to $1.0M (from $0.7M) on increased manufacturing costs for paridiprubart.","Cash at Dec 31, 2024 was $1.6M; subsequent $15M preferred/common private placement closed.","Company plans IND for EB06 (anti-CXCL10) in vitiligo Phase 2; FDA submission mid-2025.","EB05 (paridiprubart) ARDS study fully funded by U.S. government; top-line vitiligo data expected within 12-18 months post clearance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174111,"accession_number":"0001171843-25-000796","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2025-02-13T23:59:59+00:00","items":["1.01","5.03","3.02","3.03","5.02","8.01","9.01"],"status":"ready","headline":"Edesa Biotech announces $15M private placement led by Velan Capital; appoints David Liu to board","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $15M from sale of Series B-1 convertible preferred shares ($10K each) and 3.47M common shares at $1.92/share.","Proceeds to fund Phase 2 study of EB06 (CXCL10 antibody) for nonsegmental vitiligo and for working capital.","Velan Capital led placement; officers/directors purchased ~$1.1M of securities.","David Liu, Senior Analyst at Velan Capital, appointed to Board of Directors effective immediately.","Company to file resale registration statement within 30 days; beneficial ownership cap of 4.99% (or 9.99% opt-in)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191061,"accession_number":"0001171843-24-006945","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2024-12-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edesa Biotech FY2024 net loss $6.2M ($1.93/sh); cash $1.0M, negative working capital","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $6.2M ($1.93/sh) vs $8.4M ($2.93/sh) prior year; operating expenses down 24% to $7.0M.","Cash and equivalents $1.0M at Sep 30; negative working capital of $0.2M.","Post-year end: $1.5M from CEO-affiliated entity + $0.6M net from ATM offering.","Pivoted EB05 (paridiprubart) to U.S. govt-funded ARDS study; plans EB06 IND submission.","Topline Phase 2 EB06 results expected 12-18 months after FDA clearance; funded subject to capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191060,"accession_number":"0001171843-24-005928","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["1.01","5.03","1.02","2.03","3.02","3.03","9.01"],"status":"ready","headline":"Edesa Biotech enters $5M securities purchase agreement with CEO; $1.54M immediate investment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO-affiliated entity invests $1,540,819 for 150 Series A-1 Preferred Shares ($10K stated value) and warrants at $3.445 conversion/exercise price.","Preferred shares convertible into 435,414 common shares; warrants cover 326,560 common shares (75% of conversion shares).","Up to $5M total investment possible; purchases over $2M require shareholder approval under Canadian law.","$10M revolving credit facility with same entity terminated; no funds drawn and no termination penalties.","Securities issued in private placement exempt from registration; subject to Canadian hold periods."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191059,"accession_number":"0001171843-24-005515","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2024-10-04T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"Edesa Biotech enters $3.87M ATM equity facility with H.C. Wainwright; terminates prior Canaccord agreement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered ATM agreement with H.C. Wainwright to sell up to $3.87M common shares at market prices; commission 3%.","Terminated prior equity distribution agreement with Canaccord Genuity (dated March 2023) effective Oct 3, 2024.","Under the Canaccord agreement, Edesa sold ~368,309 shares for ~$2.0M proceeds; no termination penalties.","No obligation to sell all shares under the new ATM; company may suspend sales at any time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207536,"accession_number":"0001171843-24-004649","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2024-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edesa Biotech reports Q3 net loss $1.7M; ARDS drug selected for U.S. government study","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $1.7M ($0.52/shr) vs $2.0M ($0.68/shr) a year ago; nine-month loss $5.2M ($1.64/shr).","Cash $2.0M; working capital $0.7M; received $300K post-quarter from Canadian govt SIF fund.","EB05 (paridiprubart) chosen for HHS-funded ARDS platform study; Edesa supplies drug and tech support.","Preparing IND for Phase 2 vitiligo study of anti-CXCL10 technology in moderate-to-severe patients.","Q3 operating expenses $1.9M, down $0.2M YoY; R&D $0.9M, down $0.1M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224962,"accession_number":"0001654954-24-008062","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2024-06-24T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"BARDA selects Edesa's paridiprubart for U.S. government-funded Phase 2 ARDS trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Paridiprubart (EB05) chosen by BARDA for a randomized, double-blind, placebo-controlled Phase 2 platform trial in all-cause ARDS.","Prior Phase 2 study showed paridiprubart reduced mortality by 84% among critically ill COVID-19 ARDS patients.","Edesa's ongoing Phase 3 study of paridiprubart in COVID-19 ARDS continues in Canada and the U.S.","BARDA contract managed via PPD (Thermo Fisher); Edesa supplies drug product and technical support.","Goal is to label paridiprubart as standard-of-care for all-cause ARDS, with biomarker sub-study to inform development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224961,"accession_number":"0001654954-24-007083","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2024-05-30T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Edesa Biotech shareholders approve 67,000-share increase to equity plan, re-elect all directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All seven director nominees elected with ~818-819 thousand votes for each; 654k broker non-votes.","Advisory vote on executive compensation approved: 677,967 for, 122,761 against, 62,400 abstain.","Plan amendment increasing shares by 67,000 approved: 660,015 for, 151,395 against, 51,718 abstain.","Approximately 47% of outstanding shares (1,517,529) represented at the meeting.","MNP LLP appointed as auditors for FY ending Sept 30, 2024 with 1,463,707 votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224960,"accession_number":"0001654954-24-005965","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2024-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edesa Biotech Q2 FY2024 net loss $1.9M ($0.58/shr); advances ARDS Phase 3 and vitiligo study","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss narrowed to $1.9M vs $2.3M YoY; six-month loss $3.5M ($1.12/shr).","Cash $2.8M at March 31; received $0.7M post-quarter from Canadian govt funding.","Expanding Phase 3 ARDS trial with EB05; up to C$23M govt support secured.","Plans to file IND for Phase 2 pulmonary fibrosis study with EB05.","Seeks U.S. approval for Phase 2 vitiligo study; pursuing strategic deals for EB01."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}